Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180
Debt
Debt-to-Equity RatioN/A
Current Ratio17.57
Quick Ratio17.57
Price-To-Earnings
Trailing P/E Ratio-8.24
Forward P/E Ratio-5.56
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.29 per share
Price / Book2.61
Profitability
EPS (Most Recent Fiscal Year)($2.31)
Net Income$-32,740,000.00
Net MarginsN/A
Return on Equity-32.95%
Return on Assets-31.40%
Miscellaneous
Employees60
Outstanding Shares26,890,000
Market Cap$511.75 million
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics Inc (NASDAQ:ODT) announced its quarterly earnings data on Monday, July, 30th. The company reported ($0.79) EPS for the quarter, beating the Zacks' consensus estimate of ($0.83) by $0.03. View Odonate Therapeutics' Earnings History.
When is Odonate Therapeutics' next earnings date?
What price target have analysts set for ODT?
3 brokerages have issued 1 year price targets for Odonate Therapeutics' stock. Their predictions range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' share price to reach $33.50 in the next twelve months. This suggests a possible upside of 76.0% from the stock's current price. View Analyst Price Targets for Odonate Therapeutics.
What is the consensus analysts' recommendation for Odonate Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Odonate Therapeutics.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Portola Pharmaceuticals (PTLA), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX), Pacira Pharmaceuticals (PCRX), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Enanta Pharmaceuticals (ENTA), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX) and Nabriva Therapeutics (NBRV).
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 51)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 64)
- Mr. John G. Lemkey, Chief Financial Officer (Age 37)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 42)
- Ms. Nicole H. Gollaher J.D., VP of Legal Affairs (Age 49)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.
Has Odonate Therapeutics been receiving favorable news coverage?
News articles about ODT stock have trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Odonate Therapeutics earned a coverage optimism score of 0.03 on Accern's scale. They also assigned media coverage about the company an impact score of 45.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Odonate Therapeutics.
Who are Odonate Therapeutics' major shareholders?
Odonate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (4.00%), Redmile Group LLC (2.27%), BlackRock Inc. (1.24%), Bank of New York Mellon Corp (0.30%), Victory Capital Management Inc. (0.29%) and Alps Advisors Inc. (0.15%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.
Which major investors are selling Odonate Therapeutics stock?
Which major investors are buying Odonate Therapeutics stock?
ODT stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of New York Mellon Corp, BlackRock Inc., Alps Advisors Inc., Redmile Group LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $19.03.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $511.75 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
